Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Adaptive, Ascending Dose-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Invasive Hemodynamics of TRV120027 in Patients with Stable Heart Failure.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs TRV 027 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
- 13 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.